Ovid Therapeutics Inc.
OVID
$0.3383
-$0.0117-3.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 566.00K | 632.00K | 568.00K | 474.00K | 392.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 566.00K | 632.00K | 568.00K | 474.00K | 392.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 566.00K | 632.00K | 568.00K | 474.00K | 392.00K |
| SG&A Expenses | 25.79M | 25.20M | 26.47M | 27.41M | 28.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.85M | 66.48M | 65.22M | 59.58M | 56.97M |
| Operating Income | -60.28M | -65.85M | -64.65M | -59.11M | -56.58M |
| Income Before Tax | -26.43M | -32.50M | -29.75M | -50.68M | -52.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.43 | -32.50 | -29.75 | -50.68 | -52.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.43M | -32.50M | -29.75M | -50.68M | -52.34M |
| EBIT | -60.28M | -65.85M | -64.65M | -59.11M | -56.58M |
| EBITDA | -59.67M | -65.26M | -64.08M | -58.55M | -56.01M |
| EPS Basic | -0.37 | -0.45 | -0.41 | -0.70 | -0.73 |
| Normalized Basic EPS | -0.22 | -0.27 | -0.25 | -0.44 | -0.46 |
| EPS Diluted | -0.38 | -0.46 | -0.42 | -0.72 | -0.74 |
| Normalized Diluted EPS | -0.22 | -0.27 | -0.25 | -0.44 | -0.46 |
| Average Basic Shares Outstanding | 283.62M | 283.30M | 282.94M | 282.56M | 282.33M |
| Average Diluted Shares Outstanding | 283.90M | 283.58M | 283.22M | 282.56M | 282.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |